ArticleiScience2020

Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality.

Paola Sanese et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.